 Abstract tissue factor, TF, is a protein involved in blood clotting and has recently been found to play a key role in cancer development and progression. It has been shown to activate several signaling pathways that promote cancer cell growth and survival, such as the PI3K, AKT and MAPK pathways. TF overexpression is associated with increased tumor aggressiveness and poor prognosis in various cancers. Various TF targeted therapies, including monoclonal antibodies, small molecule inhibitors and immunotherapies, have been developed and are currently being tested in preclinical and clinical trials. Additionally, TF conjugated nanoparticles have shown promise in treating cancer, while TF targeted and retargeted therapies are being investigated as potential treatments for cancer. Despite the progress made, there remain many challenges and opportunities for further research into the role of TF in cancer development and progression. This article was authored by Sada Smaila Modi, Ashkan Shabana's had, Amir Kareezi and others. We are article.tv, links in the description below.